Experimental data suggesting an adrenergic mechanism in the production of parkinsonian symptoms.
D006916:5-Hydroxytryptophan / Q000494:pharmacology; D000818:Animals; D001285:Atropine / Q000494:pharmacology; D003000:Clonidine / Q000494:pharmacology; D005260:Female; D010134:Fenclonine / Q000494:pharmacology; D007099:Imipramine / Q000494:pharmacology; D008297:Male; D051379:Mice; D008815:Mice, Inbred Strains; D009538:Nicotine / Q000494:pharmacology; D010095:Oxotremorine / Q000494:pharmacology; D010302:Parkinson Disease, Secondary / Q000139:chemically induced / Q000503:physiopathology*; D010643:Phenoxybenzamine / Q000494:pharmacology; D010863:Piloerection / Q000187:drug effects; D011738:Pyrilamine / Q000494:pharmacology; D011817:Rabbits; D012472:Salivation / Q000187:drug effects; D013564:Sympathetic Nervous System / Q000503:physiopathology*; D014196:Trazodone / Q000031:analogs & derivatives / Q000494:pharmacology; D014202:Tremor / Q000139:chemically induced / Q000503:physiopathology
D010643:Phenoxybenzamine; D010095:Oxotremorine; D009538:Nicotine; D001285:Atropine; D006916:5-Hydroxytryptophan; D011738:Pyrilamine; D003000:Clonidine; D007099:Imipramine; D010134:Fenclonine; D014196:Trazodone